RNA-based gene therapy developer Rznomics will join Lilly Gateway Labs (LGL) in San Diego, California, tightening its ties with the U.S. drugmaker.
LGL is designed to support biotech innovation by providing access to strategic capital, lab space and technology, and R&D capabilities.
South Korea-based Rznomics says it plans to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while also establishing global clinical infrastructure for its lead pipelines, expanding global strategic partnerships, and recruiting top-tier R&D researchers in the U.S.
Rznomics' Trans-Splicing Ribozyme (TSR) technology is designed to avoid direct DNA editing. It removes targeted RNA and then replaces it with therapeutic RNA; it demonstrates the possibility of dual function with a single substance. It also can be programmed to deliver customized drugs to the target gene.
Back in May 2025, Rznomics inked a potential $1.3 billion deal allowing Lilly to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform. The deal focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!